IBUPROFEN
Lumbar Disc Disease
St Joseph University, Beirut, LebanonSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Lumbar Disc Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NEPENTHE Brigham and Women's Hospital | Phase 4 | BB |
Oxycodone Brigham and Women's Hospital | Phase 4 | BB |
Pentoxifylline St Joseph University, Beirut, Lebanon | Phase 4 | BB |
AUTOLOGOUS CONDITIONED PLASMA Allmed Medical Center | Phase 2 | BB |
Rexlemestrocel-L Mesoblast, Ltd. | Phase 3 | BB |
View all 15 →
Same molecule, other indications
IBUPROFEN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →